Nicotine psychopharmacology research: Advancing science, public health, and global policy

Psychopharmacology

Volumn 184, Issue 3-4, 2006, Pages 263-265

  Henningfield, Jack E ^a,b   Stolerman, Ian P ^c   Miczek, Klaus A ^d  

^a PINNEY ASSOCIATES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETALDEHYDE; MECAMYLAMINE; NICOTINE;

ANIMAL BEHAVIOR; CIGARETTE SMOKING; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG RESEARCH; DRUG SELF ADMINISTRATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; LEARNING; MEMORY; NEUROPHARMACOLOGY; NONHUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PUBLICATION;

ANIMALS; DIFFUSION OF INNOVATION; HEALTH POLICY; HUMANS; NICOTINE; PUBLIC HEALTH; RESEARCH; WORLD HEALTH;

EID: 32844458283     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0297-8     Document Type: Conference Paper

References (28)

1. Balfour DJ, Fagerstrom KO (1996) Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72:51-81
2. Balfour D, Scerri C, Stewart C, Breen K et al (2006) The effects of chronic nicotine on spatial learning and cell proliferation in the dendate gyrus of the rat. Psychopharmacology (present special issue)
3. Barry H III (2006) Commentary. Psychopharmacology (in press)
4. Belluzzi JD, Wang R, Leslie FM (2005) Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 30:705-712
5. Corrigall WA (1999) Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1:11-20
6. Corrigall WP, Coen KM (1989) Nicotine maintains robust self-administration in rats on a limited access schedule. Psychopharmacology 99:473-478
7. De Noble VJ, Mele PC (2006) Psychopharmacology (in press)
8. Food and Drug Administration (1995) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Fed Regist 60:41314-41792
9. Food and Drug Administration (1996) Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Fed Regist 61:44396-45318
10. Garrett B, Dwoskin L, Bardo M, Henningfield JE (2004) Behavioral pharmacology of nicotine reinforcement. In: Boyle P, Gray N, Henningfield J, Seffrin J, Zatonski W (eds) Tobacco and public health: science and policy. Oxford University Press, Oxford, pp 149-165
11. Goldberg SR, Spealman RD, Goldberg DM (1981) Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214:573-575
12. Henningfield JE, Stolerman I (2005) Co-chairs and introduction to plenary symposium: nicotine psychopharmacology and policy - a look behind and a look ahead. American Psychological Association, National Meeting, Washington, DC, 18 August 2005
13. Hurt RD, Robertson CR (1998) Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA 280(13):1173-1181
14. Kessler D (2001) A question of intent: a great American battle with a deadly industry. Public Affairs, New York
15. Kessler D, Henningfield JE (1995) Statement of David Kessler, Commissioner of Food and Drugs, Food and Drug Administration, accompanied by Jack E. Henningfield, Chief, Clinical Pharmacology Branch, National Institute on Drug Abuse. Hearings before the subcommittee on health and the environment of the committee on energy and commerce, House of Representatives, One Hundred Third Congress, Second Session. U.S. Government Printing Office, Washington, DC, pp 36-37
16. Langley JN (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol (Lond) 33:374-413
17. Levin E (2006) Nicotinic effects on cognitive behavioral (in press)
18. Lewin L (1998) Phantastica: a classic survey on the use and abuse of mind-altering plants. Park Street, Rochester, VT
19. Schwartz J (1994a) Philip Morris accused of stifling study. Washington Post, p A.01, 1 April, 1994
20. Schwartz J (1994b) Scientists testify tobacco company suppressed addiction studies. Washington Post, p A.36, 29 April 1994
21. Slade J, Bero LA, Hanauer P, Barnes DE, Glantz SA (1995) Nicotine and addiction. The Brown and Williamson documents. JAMA 274:225-233
22. Vagg R, Chapman S (2005) Nicotine analogues: a review of tobacco industry research interests. Addiction 100:701-712
23. Wayne GF, Connolly GN, Henningfield JE (2004) Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob Res 6:927-940
24. World Bank (1999) Curbing the epidemic: governments and the economics of tobacco control. World Health Organization, Washington, DC
25. World Health Organization (2001) Advancing knowledge on regulating tobacco products. World Health Organization, Geneva, Switzerland
26. World Health Organization (2004) Recommendation: guiding principles for the development of tobacco product research and testing capacity and proposed protocols for the initiation of tobacco product testing. Geneva, Switzerland: World Health Organization, Study Group on Tobacco Product Regulation (TobReg). Retrieved from http://www.who.int/tobacco/globa-1_interaction/tobreg/ goa_2003_principles/en/
27. World Health Organization (2005) WHO framework convention on tobacco control. WHO Document Production Services, Geneva, Switzerland
28. Zacny JP (2005) From the president's desk. Psychopharmacology and substance abuse news 38(1):1-3 http://www.apa.org/divisions/div28/newsletter/ archive/News_2005_38_1.pdf